Nicotinamide Mononucleotide (NMN) for Cardiovascular Disease

Verdict: Weak, surrogate-only evidence for heart health

NMN has not been shown to prevent or treat cardiovascular disease. The few small human trials report only minor changes in surrogate markers like blood pressure and arterial stiffness, with no evidence on heart attacks, stroke, or survival.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade is held to Weak because every human result rests on surrogate endpoints rather than real cardiovascular events. A 2026 meta-analysis of 10 RCTs (PMID 41901064, n=349) found diastolic blood pressure fell by just 2.15 mmHg (p=0.006), while the systolic drop of 1.58 mmHg was not statistically significant; a larger systolic effect appeared only in the over-60 subgroup. An effect this small is of uncertain clinical importance.

The only arterial-stiffness trial (PMID 36797393, n=36, 12 weeks) missed its primary outcome: pulse-wave velocity showed no significant difference versus placebo overall, reaching significance only in a high-BMI, high-glucose subgroup. That study was funded by a supplement company (DHC Corporation), which is why the engine flags industry-funding bias. No trial has measured heart attacks, stroke, or mortality, and most supporting data are animal or mechanistic.

Regulators and major clinics offer no endorsement for this use. The US FDA states NMN 'is excluded from the definition of a dietary supplement,' and EFSA's opinion is purely about safety, deeming up to 300 mg/day safe for the general population, not effective for the heart. NIH ODS, Mayo Clinic, Cleveland Clinic, and Harvard Health have issued no cardiovascular position, reflecting that mainstream medicine does not yet recognize NMN for cardiovascular disease.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.51
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
57%
Conflicting evidence
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.55
L3 MechanismPlausibility
0.65
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.508
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (2)L2 · primary research & systematic reviews

Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of RCTs
PMID: 41901064 2026 統合分析 n = 349
Finding: DBP reduced by 2.15 mmHg (p=0.006); SBP reduction of 1.58 mmHg not significant; SBP fell 3.94 mmHg in age >=60 subgroup.
Academic Effect size: DBP MD -2.15 mmHg (95% CI -3.68 to -0.61); SBP MD -1.58 mmHg (95% CI -3.69 to 0.53, NS)
View on PubMed
NAD metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial
PMID: 36797393 2023 RCT (double-blind) n = 36
Finding: baPWV tended to decrease in NMN group but no significant between-group difference; significant baPWV reduction only in high-BMI/high-glucose subgroup.
🟠 Limited quality ⚠️ Industry-funded
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Against
NMN is excluded from the definition of a dietary supplement source↗
L4b EU EFSA
Neutral
EFSA considers a daily intake of 300 mg of NMN to be safe for the general population, excluding pregnant and lactating women. source↗
L4d TW TFDA / 衛福部
Cautious
違反食品安全衛生管理法第28條規定 source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬2 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cardiovascular-disease-INT-nicotinamide-mononucleotide-001 繁體中文版 →